Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Prime Medicine Inc (NASDAQ: PRME) closed at $4.03 in the last session, down -4.05% from day before closing price of $4.20. In other words, the price has decreased by -$4.05 from its previous closing price. On the day, 0.72 million shares were traded. PRME stock price reached its highest trading level at $4.33 during the session, while it also had its lowest trading level at $4.0.
Ratios:
We take a closer look at PRME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.23 and its Current Ratio is at 8.23. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on May 20, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On May 16, 2024, Citigroup Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $10.
On April 22, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $17.Chardan Capital Markets initiated its Buy rating on April 22, 2024, with a $17 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 15 ’24 when NELSEN ROBERT bought 3,200,000 shares for $6.25 per share. The transaction valued at 20,000,000 led to the insider holds 3,200,000 shares of the business.
ARCH Venture Partners XII, LLC bought 3,200,000 shares of PRME for $20,000,000 on Feb 15 ’24. The 10% Owner now owns 3,200,000 shares after completing the transaction at $6.25 per share. On Feb 15 ’24, another insider, ARCH Venture Partners X, LLC, who serves as the 10% Owner of the company, bought 3,200,000 shares for $6.25 each. As a result, the insider paid 20,000,000 and bolstered with 3,200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 483724960 and an Enterprise Value of 347407776. For the stock, the TTM Price-to-Sale (P/S) ratio is 819.87 while its Price-to-Book (P/B) ratio in mrq is 2.46. Its current Enterprise Value per Revenue stands at 587.83 whereas that against EBITDA is -1.697.
Stock Price History:
Over the past 52 weeks, PRME has reached a high of $9.86, while it has fallen to a 52-week low of $3.28. The 50-Day Moving Average of the stock is 2.69%, while the 200-Day Moving Average is calculated to be -29.99%.
Shares Statistics:
According to the various share statistics, PRME traded on average about 1.39M shares per day over the past 3-months and 1139460 shares per day over the past 10 days. A total of 97.38M shares are outstanding, with a floating share count of 39.57M. Insiders hold about 67.03% of the company’s shares, while institutions hold 36.59% stake in the company. Shares short for PRME as of 1728950400 were 17635877 with a Short Ratio of 12.71, compared to 1726185600 on 16573943. Therefore, it implies a Short% of Shares Outstanding of 17635877 and a Short% of Float of 30.869999999999997.
